Your browser doesn't support javascript.
loading
Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-ß inhibitor galunisertib in patients with pancreatic cancer.
Gueorguieva, Ivelina; Tabernero, Josep; Melisi, Davide; Macarulla, Teresa; Merz, Valeria; Waterhouse, Timothy H; Miles, Colin; Lahn, Michael M; Cleverly, Ann; Benhadji, Karim A.
Afiliação
  • Gueorguieva I; Global PK/PD, Eli Lilly and Company, Sunninghill Road, Erl Wood Manor, ROB building, Windlesham, Surrey, GU20 6PH, UK. gueorguieva_ivelina@lilly.com.
  • Tabernero J; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), IOB-Quiron, Barcelona, Spain.
  • Melisi D; Digestive Molecular Clinical Oncology, University of Verona, Verona, Italy.
  • Macarulla T; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), IOB-Quiron, Barcelona, Spain.
  • Merz V; Digestive Molecular Clinical Oncology, University of Verona, Verona, Italy.
  • Waterhouse TH; Eli Lilly and Company, Indianapolis, IN, USA.
  • Miles C; Global PK/PD, Eli Lilly and Company, Sunninghill Road, Erl Wood Manor, ROB building, Windlesham, Surrey, GU20 6PH, UK.
  • Lahn MM; Eli Lilly and Company, Indianapolis, IN, USA.
  • Cleverly A; Global PK/PD, Eli Lilly and Company, Sunninghill Road, Erl Wood Manor, ROB building, Windlesham, Surrey, GU20 6PH, UK.
  • Benhadji KA; Eli Lilly and Company, Bridgewater, NJ, USA.
Cancer Chemother Pharmacol ; 84(5): 1003-1015, 2019 Nov.
Article em En | MEDLINE | ID: mdl-31482224

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Antígeno CA-19-9 Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Antígeno CA-19-9 Idioma: En Ano de publicação: 2019 Tipo de documento: Article